RB1 and breast cancer: Although RBNSig-BC was able to identify aggressive tumors with poor outcome in relatively old retrospective clinical cohorts such as TCGA and Metabric, we also acknowledge the established association between RB1 defects and sensitivity to chemotherapy (38–41).